The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Novo Joins Hands with MSD in Oral Semaglutide Promotion
Novo Nordisk Pharma and MSD said on December 9 that they have entered into a sales collaboration pact to copromote the Danish diabetes powerhouse’s oral GLP-1 agent semaglutide in Japan.In Japan, once-daily oral semaglutide was filed in July this year…
To read the full story
Related Article
- Novo Training Its Sights on Oral Diabetes Market with Rybelsus, Not Switches from GLP-1 Injectables
February 17, 2021
- 1st Oral GLP Agent Hits Japan Shelves
February 8, 2021
- Diabetes Market Regaining Momentum with New Launches; First Oral GLP-1 a Game Changer?
July 13, 2020
- Novo Files Oral Semaglutide in Japan
July 25, 2019
BUSINESS
- Takeda Taps Halozyme’s Delivery Tech to Develop New Entyvio SC Formulation
January 13, 2026
- Japan Heart Failure Drug Market Seen 1.5-Fold Growth by 2030: Fuji Keizai
January 13, 2026
- Daito Secures China Approval for EquMet Generic
January 13, 2026
- Japan Ethical Drug Sales Edge Up 0.4% in November: Crecon
January 13, 2026
- Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…